REG - Smith & Nephew Plc - Director/PDMR Shareholding

Smith & NephewAnnouncement

30/05/2025 13:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250530:nRSd8463Ka&default-theme=true

RNS Number : 8463K  Smith & Nephew Plc  30 May 2025

SMITH & NEPHEW PLC

 

30 May 2025

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

This announcement is made in accordance with the UK Market Abuse Regulation
(Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018).

 

 Reason for the notification
 Initial notification /Amendment                              Initial notification
 Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
 Name                                                         Smith & Nephew plc
 LEI                                                          213800ZTMDN8S67S1H61
 Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 Description of the financial instrument, type of instrument  Smith & Nephew plc ordinary shares of USD 0.20 each

 Identification code                                          ISIN: GB0009223206
 Nature of the transaction                                    Purchase of ordinary shares through the Company's Dividend Re-Investment Plan
                                                              following the 2024 final dividend payment on 28 May 2025.
 Date of Transaction                                          2025 - 05 - 28
 Place of Transaction                                         London Stock Exchange (XLON)

 

 Name                                                                      Director / PDMR  Price (£)   Volume       Aggregated information

 (Position)
 Helen Barraclough                                                         PDMR             10.65669    803.57057    N/A Single Transaction

 (Group General Counsel and Company Secretary)
 Craig Gaffin                                                              PDMR             10.65669    331.91224    N/A Single Transaction

 (President, Global Orthopaedics)
 Paul Connolly                                                             PDMR             10.65669    701.28312    N/A Single Transaction

 (President, Global Operations)
 Phil Cowdy                                                                PDMR             10.65669    250.51541    N/A Single Transaction

 Chief Corporate Development & Corporate Affairs Officer
 Mizanu Kebede                                                             PDMR             10.65669    553.43002    N/A Single Transaction

 (Chief Quality & Regulatory Affairs Officer)
 Deepak Nath                                                               Director         10.65669    3,457.19103  N/A Single Transaction

 (Chief Executive Officer)
 Alison Parkes                                                             PDMR             10.65669    93.4531      N/A Single Transaction

 (Chief Compliance Officer)
 Scott Schaffner                                                           PDMR             10.65669    1,327.82169  N/A Single Transaction

 (President, Sports Medicine)
 Rohit Kashyap                                                             PDMR             10.65669    332.8502     N/A Single Transaction

 (President, Advanced Wound Management and Global Commercial Operations)
 Elga Lohler                                                               PDMR             10.65669    411.65422    N/A Single Transaction

 (Chief HR Officer)

 

 

 

 

Philip Horner

Deputy Company Secretary

Smith & Nephew plc

 

Tel:  +44 (0)1923 477100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFLFEDIIVIE